サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1676132

医薬品薬事の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2025年～2033年）

Global Pharmaceutical Regulatory Affairs Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日
ページ情報
英文 162 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
医薬品薬事の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2025年～2033年）
出版日: 2025年03月01日
発行: Value Market Research
ページ情報: 英文 162 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

医薬品薬事の世界市場規模は、2024年の82億5,000万米ドルから2033年には162億8,000万米ドルに成長し、2026年から2033年の予測期間中に7.84％の堅調な年間平均成長率（CAGR）を示すと予測されます。

医薬品薬事市場は、世界の製薬業界が規制当局の監視の強化や進化する基準への準拠の必要性に直面していることから、大きな成長を遂げようとしています。薬事業務の専門家は、医薬品が市場に出回る前に必要な法的要件や安全要件を満たしていることを確認する上で重要な役割を果たしています。医薬品開発プロセスが複雑化し、患者の安全性と製品の有効性が重視されるようになったことで、薬事業務の需要が高まっています。製薬会社が複雑な規制状況を乗り切ろうとする中、薬事市場は拡大が見込まれています。

技術の進歩は、医薬品規制関連業務市場の将来を形作る上で極めて重要な役割を果たしています。データ管理、分析、薬事申請プロセスにおける革新は、薬事コンプライアンスへの取り組みの効率と精度を高めています。さらに、人工知能と機械学習の統合により、規制当局の専門家は膨大な量のデータを分析し、潜在的な規制上の課題を予測できるようになっています。企業がテクノロジー主導のソリューションへの投資を続ける中、医薬品規制関連業務市場は、医薬品開発、臨床試験、市販後調査など、さまざまな分野で導入が進むとみられます。

さらに、世界化と規制基準の調和が重視されるようになり、医薬品薬事市場の成長軌道に影響を与えています。製薬企業が新たな市場に事業を拡大するにつれ、多様な規制環境に対応できる薬事専門家への需要が高まると予想されます。この動向は、薬事業務の専門家と国際的な規制機関との連携を促進し、世界の基準への準拠を確実なものにしています。市場が進化し続ける中、テクノロジーの統合、規制の調和、戦略的パートナーシップが成功の重要な要因となるでしょう。

当社のレポートは、様々な業界や市場に関する包括的かつ実用的な洞察をお客様に提供するために綿密に作成されています。各レポートは、市場情勢を完全に理解するために、いくつかの重要な要素を含んでいます：

市場概要：市場概要：定義、分類、業界の現状など、市場に関する詳細なイントロダクション。

市場促進要因：市場成長に影響を与える主な促進要因・抑制要因・市場促進要因・課題を詳細に分析します。このセクションでは、技術の進歩、規制の変更、新たな動向などの要因を検証します。

セグメンテーション分析：製品タイプ、用途、エンドユーザー、地域などの基準に基づき、市場を明確なセグメントに内訳。この分析により、各セグメントの業績と将来性を明らかにします。

競合情勢：市場シェア、製品ポートフォリオ、戦略的イニシアティブ、財務実績など、主要市場企業の包括的評価。主要企業が採用する競合力学と主要戦略に関する考察を提供します。

市場予測：過去のデータと現在の市場状況に基づき、一定期間における市場規模と成長動向を予測します。これには、定量的分析と将来の市場軌跡を示すグラフ表示が含まれます。

地域分析：地域ごとの市場パフォーマンスを評価し、主要市場や地域動向を明らかにします。地域の市場力学とビジネスチャンスを理解するのに役立ちます。

新たな動向と機会：現在の市場動向と新たな市場動向、技術革新、潜在的な投資対象分野を特定します。将来の市場開拓と成長見通しに関する洞察を提供します。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 医薬品薬事業界分析

  • イントロダクション-市場力学
  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 医薬品薬事の世界市場分析：サービスプロバイダー別

  • 概要：サービスプロバイダー別
  • 実績および予測データ分析：サービスプロバイダー別
  • インハウス
  • アウトソーシング

第6章 医薬品薬事の世界市場分析：サービス別

  • 概要：サービス別
  • 実績および予測データ分析：サービス別
  • 薬事コンサルティング
  • 法的代理
  • レギュラトリーライティング＆出版
  • 製品登録および臨床試験申請
  • その他

第7章 医薬品薬事の世界市場分析：カテゴリー別

  • 概要：カテゴリー別
  • 実績および予測データ分析：カテゴリー別
  • 医薬品
  • 生物製剤

第8章 医薬品規制業務の世界市場分析：適応症別

  • 概要：適応症別
  • 実績および予測データ分析：適応症別
  • がん領域
  • 神経学
  • 循環器
  • 免疫学
  • その他

第9章 医薬品規制業務の世界市場分析：開発ステージ別

  • 概要：開発ステージ別
  • 実績および予測データ分析：開発ステージ別
  • 前臨床
  • 臨床
  • 市販後承認（PMA）

第10章 医薬品薬事の世界市場分析：企業規模別

  • 概要：企業規模別
  • 実績および予測データ分析：企業規模別
  • 小規模
  • 中規模
  • 大企業

第11章 医薬品薬事の世界市場分析：地域別

  • 地域別の展望
  • イントロダクション
  • 北米の売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋の売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋
  • ラテンアメリカの売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第12章 医薬品薬事企業の競合状況

  • 医薬品薬事市場の競合
  • 提携/協力/合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第13章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Freyr
  • IQVIA Inc
  • ICON Plc
  • WuXi AppTec（WAI）
  • Charles River Laboratories International Inc.
  • Labcorp Drug Development
  • Parexel International Corporation
  • Pharmalex GmbH
  • Pharmexon
  • Genpact
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Service Provider (USD MN)
  • In-House Market Sales By Geography (USD MN)
  • Outsourcing Market Sales By Geography (USD MN)
  • Analysis By Service (USD MN)
  • Regulatory Consulting Market Sales By Geography (USD MN)
  • Legal Representation Market Sales By Geography (USD MN)
  • Regulatory Writing & Publishing Market Sales By Geography (USD MN)
  • Product Registration & Clinical Trial Applications Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Category (USD MN)
  • Drugs Market Sales By Geography (USD MN)
  • Biologics Market Sales By Geography (USD MN)
  • Analysis By Indication (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Neurology Market Sales By Geography (USD MN)
  • Cardiology Market Sales By Geography (USD MN)
  • Immunology Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Development Stage (USD MN)
  • Preclinical Market Sales By Geography (USD MN)
  • Clinical Market Sales By Geography (USD MN)
  • Post Market Approval (Pma) Market Sales By Geography (USD MN)
  • Analysis By Company Size (USD MN)
  • Small Market Sales By Geography (USD MN)
  • Medium Market Sales By Geography (USD MN)
  • Large Market Sales By Geography (USD MN)
  • Global Pharmaceutical Regulatory Affairs Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Pharmaceutical Regulatory Affairs Report
  • Market Research Process
  • Market Research Methodology
  • Global Pharmaceutical Regulatory Affairs Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Service Provider
  • Market Attractiveness Analysis By Service
  • Market Attractiveness Analysis By Category
  • Market Attractiveness Analysis By Indication
  • Market Attractiveness Analysis By Development Stage
  • Market Attractiveness Analysis By Company Size
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Service Provider (USD MN)
  • In-House Market Sales By Geography (USD MN)
  • Outsourcing Market Sales By Geography (USD MN)
  • Global Market Analysis By Service (USD MN)
  • Regulatory Consulting Market Sales By Geography (USD MN)
  • Legal Representation Market Sales By Geography (USD MN)
  • Regulatory Writing & Publishing Market Sales By Geography (USD MN)
  • Product Registration & Clinical Trial Applications Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Category (USD MN)
  • Drugs Market Sales By Geography (USD MN)
  • Biologics Market Sales By Geography (USD MN)
  • Global Market Analysis By Indication (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Neurology Market Sales By Geography (USD MN)
  • Cardiology Market Sales By Geography (USD MN)
  • Immunology Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Development Stage (USD MN)
  • Preclinical Market Sales By Geography (USD MN)
  • Clinical Market Sales By Geography (USD MN)
  • Post Market Approval (Pma) Market Sales By Geography (USD MN)
  • Global Market Analysis By Company Size (USD MN)
  • Small Market Sales By Geography (USD MN)
  • Medium Market Sales By Geography (USD MN)
  • Large Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
目次
Product Code: VMR112112255

Global Pharmaceutical Regulatory Affairs Market size is anticipated to grow from USD 8.25 Billion in 2024 to USD 16.28 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 7.84% during the forecast period of 2026 to 2033.

The Pharmaceutical Regulatory Affairs Market is poised for significant growth as the global pharmaceutical industry faces increasing regulatory scrutiny and the need for compliance with evolving standards. Regulatory affairs professionals play a crucial role in ensuring that pharmaceutical products meet the necessary legal and safety requirements before they reach the market. The rising complexity of drug development processes, coupled with the growing emphasis on patient safety and product efficacy, is driving demand for regulatory affairs services. As pharmaceutical companies seek to navigate the intricate regulatory landscape, the market for regulatory affairs is expected to expand.

Technological advancements are playing a pivotal role in shaping the future of the pharmaceutical regulatory affairs market. Innovations in data management, analytics, and regulatory submission processes are enhancing the efficiency and accuracy of regulatory compliance efforts. Additionally, the integration of artificial intelligence and machine learning is enabling regulatory professionals to analyze vast amounts of data and predict potential regulatory challenges. As companies continue to invest in technology-driven solutions, the pharmaceutical regulatory affairs market is likely to see increased adoption across various segments, including drug development, clinical trials, and post-market surveillance.

Moreover, the growing emphasis on globalization and harmonization of regulatory standards is influencing the pharmaceutical regulatory affairs market's growth trajectory. As pharmaceutical companies expand their operations into new markets, the demand for regulatory expertise that can navigate diverse regulatory environments is expected to rise. This trend is driving collaboration between regulatory affairs professionals and international regulatory bodies to ensure compliance with global standards. As the market continues to evolve, the integration of technology, regulatory harmonization, and strategic partnerships will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Service Provider

  • In-house
  • Outsourcing

By Service

  • Regulatory Consulting
  • Legal Representation
  • Regulatory Writing & Publishing
  • Product Registration & Clinical Trial Applications
  • Other Services

By Category

  • Drugs
  • Biologics

By Indication

  • Oncology
  • Neurology
  • Cardiology
  • Immunology
  • Others

By Development Stage

  • Preclinical
  • Clinical
  • Post Market Approval (PMA)
  • BY Company Size
  • Small
  • Medium
  • Large
  • COMPANIES PROFILED
  • Freyr
  • IQVIA Inc
  • ICON plc
  • WuXi AppTec (WAI)
  • Charles River Laboratories International Inc.
  • Labcorp Drug Development
  • Parexel International Corporation
  • Pharmalex GmbH
  • Pharmexon
  • Genpact
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. PHARMACEUTICAL REGULATORY AFFAIRS INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Service Provider
    • 3.7.2 Market Attractiveness Analysis By Service
    • 3.7.3 Market Attractiveness Analysis By Category
    • 3.7.4 Market Attractiveness Analysis By Indication
    • 3.7.5 Market Attractiveness Analysis By Development Stage
    • 3.7.6 Market Attractiveness Analysis By Company Size
    • 3.7.7 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY SERVICE PROVIDER

  • 5.1. Overview By Service Provider
  • 5.2. Historical and Forecast Data Analysis By Service Provider
  • 5.3. In-House Historic and Forecast Sales By Regions
  • 5.4. Outsourcing Historic and Forecast Sales By Regions

6. GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY SERVICE

  • 6.1. Overview By Service
  • 6.2. Historical and Forecast Data Analysis By Service
  • 6.3. Regulatory Consulting Historic and Forecast Sales By Regions
  • 6.4. Legal Representation Historic and Forecast Sales By Regions
  • 6.5. Regulatory Writing & Publishing Historic and Forecast Sales By Regions
  • 6.6. Product Registration & Clinical Trial Applications Historic and Forecast Sales By Regions
  • 6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY CATEGORY

  • 7.1. Overview By Category
  • 7.2. Historical and Forecast Data Analysis By Category
  • 7.3. Drugs Historic and Forecast Sales By Regions
  • 7.4. Biologics Historic and Forecast Sales By Regions

8. GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY INDICATION

  • 8.1. Overview By Indication
  • 8.2. Historical and Forecast Data Analysis By Indication
  • 8.3. Oncology Historic and Forecast Sales By Regions
  • 8.4. Neurology Historic and Forecast Sales By Regions
  • 8.5. Cardiology Historic and Forecast Sales By Regions
  • 8.6. Immunology Historic and Forecast Sales By Regions
  • 8.7. Others Historic and Forecast Sales By Regions

9. GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY DEVELOPMENT STAGE

  • 9.1. Overview By Development Stage
  • 9.2. Historical and Forecast Data Analysis By Development Stage
  • 9.3. Preclinical Historic and Forecast Sales By Regions
  • 9.4. Clinical Historic and Forecast Sales By Regions
  • 9.5. Post Market Approval (Pma) Historic and Forecast Sales By Regions

10. GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY COMPANY SIZE

  • 10.1. Overview By Company Size
  • 10.2. Historical and Forecast Data Analysis By Company Size
  • 10.3. Small Historic and Forecast Sales By Regions
  • 10.4. Medium Historic and Forecast Sales By Regions
  • 10.5. Large Historic and Forecast Sales By Regions

11. GLOBAL PHARMACEUTICAL REGULATORY AFFAIRS MARKET ANALYSIS BY GEOGRAPHY

  • 11.1. Regional Outlook
  • 11.2. Introduction
  • 11.3. North America Sales Analysis
    • 11.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.3.2 North America By Segment Sales Analysis
    • 11.3.3 North America By Country Sales Analysis
    • 11.3.4 United States Sales Analysis
    • 11.3.5 Canada Sales Analysis
    • 11.3.6 Mexico Sales Analysis
  • 11.4. Europe Sales Analysis
    • 11.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.4.2 Europe By Segment Sales Analysis
    • 11.4.3 Europe By Country Sales Analysis
    • 11.4.4 United Kingdom Sales Analysis
    • 11.4.5 France Sales Analysis
    • 11.4.6 Germany Sales Analysis
    • 11.4.7 Italy Sales Analysis
    • 11.4.8 Russia Sales Analysis
    • 11.4.9 Rest Of Europe Sales Analysis
  • 11.5. Asia Pacific Sales Analysis
    • 11.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.5.2 Asia Pacific By Segment Sales Analysis
    • 11.5.3 Asia Pacific By Country Sales Analysis
    • 11.5.4 China Sales Analysis
    • 11.5.5 India Sales Analysis
    • 11.5.6 Japan Sales Analysis
    • 11.5.7 South Korea Sales Analysis
    • 11.5.8 Australia Sales Analysis
    • 11.5.9 South East Asia Sales Analysis
    • 11.5.10 Rest Of Asia Pacific Sales Analysis
  • 11.6. Latin America Sales Analysis
    • 11.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.6.2 Latin America By Segment Sales Analysis
    • 11.6.3 Latin America By Country Sales Analysis
    • 11.6.4 Brazil Sales Analysis
    • 11.6.5 Argentina Sales Analysis
    • 11.6.6 Peru Sales Analysis
    • 11.6.7 Chile Sales Analysis
    • 11.6.8 Rest of Latin America Sales Analysis
  • 11.7. Middle East & Africa Sales Analysis
    • 11.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.7.2 Middle East & Africa By Segment Sales Analysis
    • 11.7.3 Middle East & Africa By Country Sales Analysis
    • 11.7.4 Saudi Arabia Sales Analysis
    • 11.7.5 UAE Sales Analysis
    • 11.7.6 Israel Sales Analysis
    • 11.7.7 South Africa Sales Analysis
    • 11.7.8 Rest Of Middle East And Africa Sales Analysis

12. COMPETITIVE LANDSCAPE OF THE PHARMACEUTICAL REGULATORY AFFAIRS COMPANIES

  • 12.1. Pharmaceutical Regulatory Affairs Market Competition
  • 12.2. Partnership/Collaboration/Agreement
  • 12.3. Merger And Acquisitions
  • 12.4. New Product Launch
  • 12.5. Other Developments

13. COMPANY PROFILES OF PHARMACEUTICAL REGULATORY AFFAIRS INDUSTRY

  • 13.1. Top Companies Market Share Analysis
  • 13.2. Market Concentration Rate
  • 13.3. Freyr
    • 13.3.1 Company Overview
    • 13.3.2 Company Revenue
    • 13.3.3 Products
    • 13.3.4 Recent Developments
  • 13.4. IQVIA Inc
    • 13.4.1 Company Overview
    • 13.4.2 Company Revenue
    • 13.4.3 Products
    • 13.4.4 Recent Developments
  • 13.5. ICON Plc
    • 13.5.1 Company Overview
    • 13.5.2 Company Revenue
    • 13.5.3 Products
    • 13.5.4 Recent Developments
  • 13.6. WuXi AppTec (WAI)
    • 13.6.1 Company Overview
    • 13.6.2 Company Revenue
    • 13.6.3 Products
    • 13.6.4 Recent Developments
  • 13.7. Charles River Laboratories International Inc.
    • 13.7.1 Company Overview
    • 13.7.2 Company Revenue
    • 13.7.3 Products
    • 13.7.4 Recent Developments
  • 13.8. Labcorp Drug Development
    • 13.8.1 Company Overview
    • 13.8.2 Company Revenue
    • 13.8.3 Products
    • 13.8.4 Recent Developments
  • 13.9. Parexel International Corporation
    • 13.9.1 Company Overview
    • 13.9.2 Company Revenue
    • 13.9.3 Products
    • 13.9.4 Recent Developments
  • 13.10. Pharmalex GmbH
    • 13.10.1 Company Overview
    • 13.10.2 Company Revenue
    • 13.10.3 Products
    • 13.10.4 Recent Developments
  • 13.11. Pharmexon
    • 13.11.1 Company Overview
    • 13.11.2 Company Revenue
    • 13.11.3 Products
    • 13.11.4 Recent Developments
  • 13.12. Genpact
    • 13.12.1 Company Overview
    • 13.12.2 Company Revenue
    • 13.12.3 Products
    • 13.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies